.png)
EUROPEAN MEDICINES AGENCY(EMA) latest updates
COVID-19: latest updates
The latest updates on the COVID-19 pandemic from the European Medicines Agency (EMA) are available below.
| DATE | TOPIC | UPDATE | MORE INFORMATION |
|---|---|---|---|
| 25/01/2022 | COVID-19 vaccines: authorised | EMA published the clinical data supporting the extension of indication for Spikevax to include use in adolescents aged 12 to 17. Health Canada also published these data | Clinical data (login required) |
| 24/01/2022 | COVID-19 vaccines: authorised | EMA's CHMP approved increased manufacturing capacity for AstraZeneca's COVID-19 vaccine Vaxzevria | Increase in manufacturing capacity for Vaxzevria (previously COVID-19 Vaccine AstraZeneca) |
| 21/01/2022 | International Coalition of Medicines Regulatory Authorities (ICMRA) | ICMRA published a report on the global regulatory response to the Omicron variant | International regulators’ recommendations on COVID-19 vaccines and the Omicron variant |
| 20/01/2022 | Safety of COVID-19 vaccines | EMA published new safety updates for COVID-19 vaccines | |
| 19/01/2022 | COVID-19 vaccines: authorised | EMA published assessment reports for its review of the risk of myocarditis and pericarditis with Comirnaty and Spikevax | |
| 18/01/2022 | COVID-19 vaccines: authorised | EMA published updated product information for Vaxzevria to include new data on the known side effect, thrombosis with thrombocytopenia syndrome | Vaxzevria (previously COVID-19 Vaccine AstraZeneca) |
| 18/01/2022 | Treatments and vaccines for COVID-19 | The video recording is available of EMA’s latest COVID-19 press briefing | EMA regular press briefing on COVID-19 |
| 18/01/2022 | COVID-19 vaccines: authorised | EMA published an update on the use of mRNA vaccines during pregnancy | COVID-19: latest safety data provide reassurance about use of mRNA vaccines during pregnancy |
Σχόλια
Δημοσίευση σχολίου
Eυπρόσδεκτα τα σχόλιά Σας...